
Tag: New York City Pension Funds


Bank of America, Goldman Sachs, Morgan Stanley Accused of Delaying on Clean Energy Financing Disclosure
NYC Comptroller seeks annual disclosure of each banks’ ratio of clean energy supply financing to fossil fuel energy supply financing.

NYC Retirement System’s Steven Meier on Rates, Risks and Opportunities in 2024

NYC, Oregon Pension Funds Named Lead Plaintiffs in Fox Lawsuit
The plaintiffs’ claim that Fox News’ business model included knowingly engaging in defamation ‘appears promising,’ a Delaware Chancery Court says.

New York City is Worried About China, and the Fed
Deputy CIO fleshes out key concerns at meeting of five city pension plans.

New York Pensions Settle Environmental Activism Lawsuit Against Aerospace Company
Multi-billion-dollar company argues greenhouse gas proposals go against its ‘ordinary business.’

NYC Pension Funds to Double Green Investments
The three-year plan will see the five-fund retirement system’s climate-related holdings go to $4 billion.
NYC Pension Funds Earn 8.7% in 2018
Returns surpass 7% rate assumption, but fall short of last year’s 12.95%.
NYC Comptroller’s Diversity Push Shows Some Results
Stringer and city pension funds succeed in broadening boards at more than half of 151 targeted companies.

CIO Scott Evans to Leave NYC Pensions at Fiscal Year-End
Evans is the third CIO to resign from a NY pension this month.

NYC Pension System to Divest $5 Billion from Fossil Fuels
Seeking climate change-related damages, city files lawsuit against five major oil companies.

NYC Pension Funds, RBC GAM Access Capital Team up for $450 Million Affordable Housing Plan
Investment includes first-of-its-kind program to support veterans.

Mylan Board Re-Elected, Beats “Vote No” Campaign
Although shareholders voted against Management Proposal 5, the directors remain.
Comptroller Stringer Creates New Working Group in Quest for Greater Diversity Gains
Positive M/WBE data drives success for NYC pension funds.
Pension Funds Oppose Mylan Board, Compensation Plan
Four pension funds say the drug maker has “reached new lows in corporate stewardship.”